Wave Life Sciences Pte. Ltd (WVE)
NASDAQ:WVE
Top Page
Wave Life Sciences
(NASDAQ:WVE)
Select Model
Select Model
Rating:52Neutral
Price Target:
$7.50
▲(3.31% Upside)
Action:ReiteratedDate:04/01/26
The score reflects weak financial performance (steep revenue decline, sizable ongoing losses, and heavy cash burn) and bearish technicals (trading well below key moving averages with negative momentum). These are partially offset by a relatively solid balance sheet with low leverage and a constructive earnings-call outlook driven by encouraging clinical signals, multiple near-term data catalysts, and cash runway into Q3 2028.
Positive Factors
Cash runway and funding
A >$600M cash balance with management guidance to fund operations into Q3 2028 materially de-risks near-term program execution. This provides durable optionality to advance multiple clinical programs, meet regulatory milestones, and absorb development cadence variability without immediate financing pressure.
Negative Factors
Heavy negative cash flow and burn
Sustained negative operating and free cash flow (~-$187M TTM) indicates the business is not yet self-funding and remains reliant on partners and capital markets. Persistent burn can erode runway absent milestones and may force dilution or reprioritization of programs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway and funding
A >$600M cash balance with management guidance to fund operations into Q3 2028 materially de-risks near-term program execution. This provides durable optionality to advance multiple clinical programs, meet regulatory milestones, and absorb development cadence variability without immediate financing pressure.
Read all positive factors
Wave Life Sciences (WVE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.35B
Dividend YieldN/A
Average Volume (3M)5.05M
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue Growth103.75%
EPS Growth33.84%
CountryUS
Employees287
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding188,254,960
10 Day Avg. Volume4,051,188
30 Day Avg. Volume5,052,922
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.45
Price to Sales (P/S)67.10
P/FCF Ratio-15.29
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue18.31
Enterprise Value/Gross Profit21.67
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$26.15Price Target Upside260.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.36
Revenue Forecast (FY)$34.23M
Wave Life Sciences Business Overview & Revenue Model
Company Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic ac...
How the Company Makes Money
Wave Life Sciences has historically generated little to no recurring product revenue because its medicines are largely in clinical development rather than commercialized. The company primarily funds operations through a combination of (1) collabor...
Wave Life Sciences Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call emphasized substantial clinical progress across multiple high-value programs (notably differentiated Phase I body-composition signals for WVE-007, compelling RNA editing results for WVE-006, and advancement of WVE-008), strong platform differentiation (SpiNA chemistry), concrete partnership milestones and a cash runway into Q3 2028. These positives are tempered by a large, one-time-driven revenue decline (Takeda termination), rising operating expenses and widening net losses, plus normal early-stage and competitive/regulatory uncertainties. On balance, the clinical and platform progress combined with an adequate cash runway and partnership upside outweigh near-term financial headwinds, but the business remains execution- and data-dependent over the next 12–18 months.Positive Updates
WVE-007 (INHBE) Phase I body-composition signal
Interim INLIGHT data (single 240 mg dose) showed a placebo-adjusted 4% reduction in total fat, a 9.2% reduction in visceral fat and a 0.9% increase in lean mass at 3 months. Company highlighted fat loss comparable to semaglutide at 12 weeks but with preservation of muscle; durable serum activin E suppression observed supporting once- or twice-yearly dosing and a clean safety profile through the 600 mg cohort.
Negative Updates
Sharp revenue decline driven by Takeda termination
Q4 revenue fell to $17.2 million from $83.7 million year-ago (≈-79.5% YoY). Full-year 2025 revenue was $42.7 million versus $108.3 million in 2024 (≈-60.6% YoY), primarily due to recognition impacts following the October 2024 termination of the Takeda collaboration.
Read all updates
Q4-2025 Updates
Positive
Negative
WVE-007 (INHBE) Phase I body-composition signal
Interim INLIGHT data (single 240 mg dose) showed a placebo-adjusted 4% reduction in total fat, a 9.2% reduction in visceral fat and a 0.9% increase in lean mass at 3 months. Company highlighted fat loss comparable to semaglutide at 12 weeks but with preservation of muscle; durable serum activin E suppression observed supporting once- or twice-yearly dosing and a clean safety profile through the 600 mg cohort.
Read all positive updates
Company Guidance
Wave reiterated that its clinical and regulatory timelines and financial runway are on track: INLIGHT will report six‑month follow‑up from the 240 mg single‑dose cohort and three‑month data from the 400 mg single‑dose cohort later this quarter, the Phase IIa multi‑dose (MAD) for WVE‑007 is planned to start in H1 2026 (with MRI and MRI‑PDFF assessments), add‑on and post‑incretin maintenance trials for 007 are slated for 2026, regulatory feedback on an accelerated approval pathway for WVE‑006 is expected mid‑2026, a CTA for WVE‑008 and an NDA submission for N531 are targeted in 2026, and RestorAATion‑2 will report 400 mg MAD data this quarter with 600 mg data in 2026; financially they reported Q4 revenue $17.2M (FY 2025 $42.7M), Q4 R&D $52.8M (FY $182.8M), Q4 G&A $20.9M (FY $75.3M), Q4 net loss $53.2M (FY net loss $204.4M), ended the year with $602.1M cash (runway into Q3 2028), expect ongoing GSK milestone payments (collaboration eligible for up to $2.8B; GSK has selected a 4th program and may advance up to 8), and highlighted clinical metrics including >100 patients dosed in INLIGHT (three therapeutic cohorts of 32 each), a single 240 mg dose producing a placebo‑adjusted 4% total fat reduction, 9.2% visceral fat reduction and a 0.9% lean‑mass increase at 3 months with durable activin E suppression (supporting once‑ or twice‑yearly dosing), and WVE‑006 showing >11 µM M‑AAT, >50% editing and an acute‑phase response at the lowest dose.Wave Life Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.73M | 108.30M | 113.31M | 3.65M | 40.96M |
| Gross Profit | 33.88M | 108.30M | 113.31M | 3.65M | 40.96M |
| EBITDA | -195.53M | -101.74M | -58.79M | -152.61M | -117.18M |
| Net Income | -204.38M | -97.01M | -57.51M | -161.82M | -122.25M |
Balance Sheet | |||||
| Total Assets | 638.50M | 352.21M | 274.95M | 146.39M | 207.01M |
| Cash, Cash Equivalents and Short-Term Investments | 602.07M | 302.08M | 200.35M | 88.50M | 150.56M |
| Total Debt | 17.77M | 25.40M | 32.12M | 37.61M | 29.92M |
| Total Liabilities | 112.27M | 142.69M | 235.32M | 191.48M | 174.51M |
| Stockholders Equity | 526.23M | 209.51M | 39.63M | -45.09M | 32.50M |
Cash Flow | |||||
| Free Cash Flow | -187.49M | -151.96M | -20.55M | -129.14M | -89.55M |
| Operating Cash Flow | -187.49M | -151.03M | -19.43M | -127.78M | -88.99M |
| Investing Cash Flow | -718.00K | -938.00K | -1.11M | -1.25M | -560.00K |
| Financing Cash Flow | 488.24M | 253.89M | 132.53M | 67.19M | 55.83M |
Wave Life Sciences Technical Analysis
Negative
7.26
Price Trends
11.79
Negative
12.51
Negative
10.20
Negative
Market Momentum
-1.61
Positive
30.35
Neutral
66.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WVE, the sentiment is Negative. The current price of 7.26 is below the 20-day moving average (MA) of 9.27, below the 50-day MA of 11.79, and below the 200-day MA of 10.20, indicating a bearish trend. The MACD of -1.61 indicates Positive momentum. The RSI at 30.35 is Neutral, neither overbought nor oversold. The STOCH value of 66.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WVE.
Wave Life Sciences Risk Analysis
Wave Life Sciences disclosed 72 risk factors in its most recent earnings report. Wave Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Wave Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $2.03B | -273.00 | -2.05% | ― | 1128.17% | ― | |
57 Neutral | $1.63B | -12.79 | -28.85% | ― | ― | -37.07% | |
52 Neutral | $1.35B | -14.03 | -84.99% | ― | 103.75% | 33.84% | |
52 Neutral | $1.02B | -5.55 | -38.79% | ― | ― | 4.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.47B | -5.08 | -8396.72% | ― | 59.20% | -155.65% | |
50 Neutral | $1.60B | -14.96 | -57.48% | ― | 1137.19% | 70.51% |
* Healthcare Sector Average
WVE
Wave Life Sciences
7.26
0.98
15.61%
PGEN
Precigen
4.17
2.73
189.58%
STOK
Stoke Therapeutics
35.05
27.30
352.26%
ORIC
Oric Pharmaceuticals
10.40
5.36
106.35%
NUVB
Nuvation Bio
4.70
2.68
132.67%
RAPP
Rapport Therapeutics, Inc.
34.65
25.05
260.94%
Wave Life Sciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Wave Life Sciences Reports Positive WVE-007 Obesity Trial Data
Positive
Mar 26, 2026
On March 26, 2026, Wave Life Sciences reported positive interim Phase 1 data from its first-in-human INLIGHT trial of WVE-007, an investigational INHBE GalNAc-siRNA, in otherwise healthy individuals with overweight or obesity. A single 240 mg dose...
Business Operations and StrategyFinancial Disclosures
Wave Life Sciences Highlights 2025 Results and Obesity Progress
Positive
Feb 26, 2026
On February 26, 2026, Wave Life Sciences reported fourth-quarter and full-year 2025 results, highlighting progress across its RNA-based pipeline and a strong cash position of $602.1 million as of December 31, 2025, providing runway into the third ...
Business Operations and StrategyProduct-Related Announcements
Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path
Positive
Feb 2, 2026
On February 2, 2026, Wave Life Sciences announced that it has regained full rights to WVE-006, its first-in-class GalNAc-conjugated RNA editing candidate for alpha-1 antitrypsin deficiency (AATD), from partner GSK, enabling the company to accelera...
Business Operations and StrategyFinancial Disclosures
Wave Life Sciences sets 2026 strategy, highlights obesity program
Positive
Jan 12, 2026
On January 12, 2026, Wave Life Sciences outlined its 2026 strategic priorities, centered on accelerating development of its investigational INHBE-targeting siRNA WVE-007 for obesity and advancing its RNA editing pipeline, while presenting at the 4...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.